Thromb Haemost 2007; 97(02): 327-328
DOI: 10.1160/TH06-11-0634
Letters to the Editor
Schattauer GmbH

The effect of a thrombin exosite 2-binding DNA aptamer (HD-22) on non-catalytic thrombinenhanced fibrin polymerization

Michael W. Mosesson
1   BloodCenter of Wisconsin, Milwaukee, Wisconsin, USA
› Author Affiliations
Further Information

Publication History

Received 07 November 2006

Accepted after revision 29 January 2006

Publication Date:
25 November 2017 (online)

 

 
  • References

  • 1 Bock PE. Active-site-selective labeling of blood coagulation proteinases with fluorescence probes by the use of thioester peptide chloromethyl ketones. II. Properties of thrombin derivatives as reporters of prothrombin fragment 2 binding and specificity of the labeling approach for other proteinases. J Biol Chem 1992; 267: 14974-14981.
  • 2 Colwell NS, Blinder MA, Tsiang M. et al. Allosteric effects of a monoclonal antibody against thrombin exosite II. Biochemistry 1998; 37: 15057-15065.
  • 3 Liaw PC, Fredenburgh JC, Stafford AR. et al. Localization of the thrombin-binding domain on prothrombin fragment 2. J Biol Chem 1998; 273: 8932-8939.
  • 4 Li Y, Spencer FA, Ball S. et al. Inhibition of plateletdependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes. J Thromb Thrombolysis 2000; 10: 69-76.
  • 5 Verhamme IM, Olson ST, Tollefsen DM. et al. Binding of exosite ligands to human thrombin. Reevaluation of allosteric linkage between thrombin exosites I and II. J Biol Chem 2002; 277: 6788-6798.
  • 6 Siebenlist KR, Mosesson MW, Hernandez I. et al. Studies on the basis for the properties of fibrin produced from fibrinogen containing g' chains. Blood 2005; 106: 2730-2736.
  • 7 Tasset DM, Kubik MF, Steiner W. Oligonucleotide inhibitors of human thrombin that bind distinct epitopes. J Mol Biol 1997; 272: 688-698.
  • 8 Fredenburgh JC, Stafford AR, Weitz JI. Evidence for allosteric linkage between exosites 1 and 2 of thrombin. J Biol Chem 1997; 272: 25493-25499.
  • 9 Bock PE, Olson ST, Bjork I. Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite I. J Biol Chem 1997; 272: 19837-19845.
  • 10 Fredenburgh JC, Stafford AR, Weitz JI. Conformational changes in thrombin when complexed by serpins. J Biol Chem 2001; 276: 44828-44834.
  • 11 Mosesson MW, Hernandez I, Siebenlist KR. Evidence that catalytically-inactivated thrombin forms non-covalently linked dimers that bridge between fibrin/ fibrinogen fibers and enhance fibrin polymerization. Biophys Chem 2004; 110: 93-100.
  • 12 Bock LC, Griffin LC, Latham JA. et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355: 564-566.
  • 13 Celikel R, McClintock RA, Roberts JR. et al. Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ibalpha. Science 2003; 301: 218-221.
  • 14 Bode W, Turk D, Karshikov A. The refined 1.9 Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone- inhibited human α -thrombin. Protein Sci 1992; 1: 426-471.
  • 15 De Cristofaro R, De Candia E, Rutella S. et al. The Asp(272)-Glu(282) region of platelet glycoprotein Ibalpha interacts with the heparin-binding site of alphathrombin and protects the enzyme from the heparincatalyzed inhibition by antithrombin III. J Biol Chem 2000; 275: 3887-3895.
  • 16 Pineda AO, Chen Z-W, Marino F. et al. Crystal structure of thrombin in complex with fibrinogen γ ' peptide. Biophys Chem. 2006. (in press).